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Abstract
Background
Well-designed phase II trials must have acceptable error rates relative to a pre-specified success criterion, usually
a statistically significant p-value. Such standard designs may not always suffice from a clinical perspective because
clinical relevance may call for more. For example, proof-of-concept in phase II often requires not only statistical
significance but also a sufficiently large effect estimate.
Purpose
We propose dual-criterion designs to complement statistical significance with clinical relevance, discuss their
methodology, and illustrate their implementation in phase II.
Methods
Clinical relevance requires the effect estimate to pass a clinically motivated threshold (the decision value). In contrast
to standard designs, the required effect estimate is an explicit design input whereas study power is implicit. The sample
size for a dual-criterion design needs careful considerations of the study’s operating characteristics (type-I error, power).
Results
Dual-criterion designs are discussed for a randomized controlled and a single-arm phase II trial, including decision
criteria, sample size calculations, decisions under various data scenarios, and operating characteristics. The designs
facilitate GO/NO-GO decisions due to their complementary statistical-clinical criterion.
Limitations
While conceptually simple, implementing a dual-criterion design needs care. The clinical decision value must be
elicited carefully in collaboration with clinicians, and understanding similarities and differences to a standard design is
crucial.
Conclusion
To improve evidence-based decision-making, a formal yet transparent quantitative framework is important. Dual-
criterion designs offer an appealing statistical-clinical compromise, which may be preferable to standard designs if
evidence against the null hypothesis alone does not suffice for an efficacy claim.
Keywords
Clinical relevance, dual-criterion, evidence, GO/NO-GO, operating characteristics, phase II design, proof-of-concept,
statistical significance
Introduction
Making evidence-based decisions is essential in drug
development. To conclude activity of a drug, such decisions
usually require a statistically significant p-value from a well-
designed trial. However, statistical significance alone may
not suffice if the trial does not deliver a clinically relevant
effect estimate (Wasserstein and Lazar1). We discuss a
simple dual-criterion design that formally combines a
statistical (significance) and clinical (effect size estimate)
criterion.
Here we focus on phase II trials, which play a key
role in drug development. In particular, Proof-of-Concept
(PoC) is a milestone, the earliest point when the efficacy
of an experimental drug is formally investigated. PoC trials
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typically lead to one of the following decisions: continue
further development (GO), stop development (NO-GO), or
seek further information.
The consequences of false decisions in phase II can
be severe. Therefore, irrespective of the chosen design,
understanding statistical error rates is important. For
example, false-positive results (type-I errors) in PoC trials
will lead to phase III trials with ineffective experimental
drugs and likely cause negative results. On the other hand,
false negative results (type-II errors) will often stop the
development of a potentially useful drug. Various phase
II design options have been proposed, with primary focus
on error rate control (e.g. Fleming2, Herson and Carter3,
Simon4, Schaid et al.5, Storer6, Liu et al.7,8, Sargent et al.9,
Korn et al.10, Rubinstein et al.11, Simon et al.12, Parashar et
al.13).
GO or NO-GO decisions should always be seen in the
context of the clinical needs and the competitive landscape
(Cartwright et al.14), which requires discussions among
clinical teams, governance boards, and key opinion leaders.
Consensus is important and easier to reach if trial results
meet a pre-defined clinical criterion. A few proposals to
formally account for a relevant effect size in clinical and
other settings have been discussed (Nicewander and Price15,
Chuang-Stein et al.16,17, Neuenschwander et al.18, Fisch et
al.19, Frewer et al.20). Here, we will discuss a simple dual-
criterion, which we have applied in many phase II trials.
We will first review three generic phase II designs:
the standard, dual-criterion, and precision design. We then
describe the dual-criterion design in more detail and show a
frequentist and Bayesian application.
Design choices for phase II trials
In this section, we introduce the main components of three
basic phase II designs: the standard, dual-criterion, and
precision design (Table 1).
The standard design
The standard design is very popular in drug development.
For comparative (treatment vs. control) trials, it puts forward
stringent statistical criteria expressed as error rates:
1. type-I error control: if there is no treatment effect (the
null hypothesis), the probability to declare success at
the end of the trial is at most α. Typical values for α
(one-sided) are 2.5% for confirmatory trials, and 5%
or 10% for early phase trials. Here, success means
statistical significance.
2. power: for a selected effect size of interest (the
alternative hypothesis), the probability of trial success
is 80% or 90%.
While the standard design prevails in the confirmatory
setting, its limitations are well-known (Senn21). The main
issue is that statistical significance only guarantees sufficient
evidence to reject the null hypothesis (no effect), which may
not suffice from a clinical perspective. Importantly, statistical
significance does not necessarily support the alternative
hypothesis, except when the p-value is highly significant.
The dual-criterion design
The dual-criterion design addresses the limitation of the
standard design. It is appealing if one wants to base trial
success not only on statistical significance but also on the
effect estimate, which is more tangible for clinicians. The
design requires the following inputs (Table 1):
1. Like the standard design, type-I error control is
needed, which requires a null hypothesis and type-I
error α. Eventually, a significant p-value will provide
sufficient evidence for a positive treatment effect.
2. Unlike the standard design, the dual-criterion design
requires a decision value, which is clinically moti-
vated. The decision value is the minimum effect esti-
mate needed for trial success. Estimates superior to
this value justify a GO decision, whereas inferior
values do not and will usually require additional con-
siderations.
Compared to the standard design, the dual-criterion design
combines the rigid statistical criteria (significant p-value,
type-I error control) with a clinical criterion that guarantees
a sufficiently large effect estimate.
The precision design
The two previous designs rely on error rates (type-I error,
power), which require clearly defined criteria for trial
success. For the special case where the null hypothesis and
other benchmark values (alternative hypothesis or decision
value) cannot be determined, a precision design may be
an option. It requires a sufficiently precise effect estimate,
usually defined via the width of the 95% confidence interval.
Example
We now illustrate the three designs with a simple
example. Consider a randomized trial with patients equally
randomized to the experimental drug and control. The
outcome of interest is the hazard-ratio (HR) for progression-
free survival (PFS), where the HR is less than one if the
experimental drug is better than the control.
The standard design requires a null hypothesis with
corresponding type-I error and an alternative parameter with
corresponding power (Table 1). For example, assume a
superiority trial (null hypothesis HR=1), one-sided type-I
error 2.5%, and 90% power under a 25% hazard reduction
(alternative hypothesis HR=0.75). The number of events to
meet these requirements is 508. For this design, statistical
significance is achieved if the estimated HR is 0.84, a
hazard reduction of 16%. Note that this estimate threshold
is implicit; that is, it follows from the design specifications.
The dual-criterion design requires a null hypothesis (with
corresponding one-sided type-I error α) and the decision
value for the effect estimate. As seen above, success for the
standard design (with n=508 events) requires an estimated
hazard reduction of at least 16%. If clinical considerations
require an estimated reduction of at least 20%, the number
of events must be at least 309 (see next section for details).
Importantly, the dual-criterion design also controls the type-
I error at 2.5%, but the power is implicit; that is, it follows
from the type-I error and the decision value criterion. For
309 events, the power is smaller than for the standard design.
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The reason is simple: an estimated hazard reduction of 20%
(the clinical criterion) is more difficult to achieve than a 16%
hazard reduction (considered clinically insufficient) for the
standard design.
For the precision design, which assumes no comparative
benchmarks (null hypothesis, alternative hypothesis, deci-
sion value), assume that the aim is to estimate the HR with
”20% precision”: 95%-interval = (HR/1.2, HR×1.2). This
requires 462 events. For ”25% precision”, 95%-interval =
(HR/1.25, HR×1.25), the number of events is 309.
[Table 1 about here.]
Dual-criterion designs: criteria, outcomes, and
decisions
The dual-criterion design is recommended for comparative
trials if the required evidence for an effect can be expressed
for two benchmarks: the null value (null hypothesis) and the
decision value for the effect estimate. For a GO-decision, the
evidence must be sufficiently strong that the effect is better
than the null value and that the effect estimate reaches the
clinically relevant decision value. The criteria are
1. statistical significance: the one-sided p-value must be
less than α. Equivalently, the one-sided 100(1− α)%
confidence interval must exclude the null value.
2. clinical relevance: the estimated effect must reach the
decision value.
Regarding the statistical criterion, 10%, 5%, and 2.5% are
commonly used for the one-sided type-I error α, depending
on the required strength of evidence to reject the null
hypothesis. The clinical criterion must be elicited from
clinical experts. Table 2 shows the four possible outcomes
of a dual-criterion design:
• case 1: if trial results fail both criteria, the decision will
be a NO-GO.
• case 2: if the statistical and clinical criteria are both
met, the decision will be a GO.
• cases 3 and 4: inconclusive situations arise when
only one criterion holds. For example, for large trials
or unexpectedly small variability of the outcome,
statistical significance may hold, yet the estimate may
miss the decision value (case 3). On the other hand,
for small trials or unexpectedly large variability of the
outcome, the effect estimate may pass the decision
value, but statistical significance may not hold (case
4).
[Table 2 about here.]
The planning of a dual-criterion trial requires carefully
selected decision criteria and sample size. The dual
criterion must be based on clinical input, which necessitates
effective collaborations between statisticians and clinicians.
Understanding the similarities and differences between a
standard and dual-criterion design is important. Graphs and
non-statistical language help to explain the main features
of a dual-criterion design. In addition, data scenarios
with respective decisions may provide further clarification.
Finally, operating characteristics (type-I error and power) are
crucial to justify the design. Details will be discussed in the
following sections.
Since decision making in phase II is complex, a final
decision in inconclusive situations should account for other
relevant information, such as key secondary endpoints,
safety, PK/PD, biomarkers, and subgroups.
In summary, recommendations for selecting a design
depend on the context, which informs the required design
inputs. In the comparative phase II setting, two benchmarks
(null value = no effect, decision value = minimum effect
estimate) will often be available, which suggests a dual-
criterion design. In other situations, a standard or precision
design may be more appropriate. Irrespective of the chosen
design, a clear understanding of the development context is
crucial, and a consensus about design inputs and decisions
related to possible trial outcomes is important.
Statistical considerations for dual-criterion
designs
This section provides the key statistical components of dual-
criterion designs. These refer to the formulation of the dual-
criterion, the determination of the sample size, and the
design’s operating characteristics.
Frequentist and Bayesian dual-criteria
The frequentist formulation of the null and decision value
has been presented in the previous section. The alternative
Bayesian version requires a sufficiently large probability for
a positive treatment effect (effect exceeds the null value) and
an effect estimate that reaches the decision value.
For the first Bayesian criterion, depending on the required
strength of evidence for a positive effect, 90%, 95%, or
97.5% are common values for 1− α. These values are
selected in analogy to their frequentist counterparts (p-value
less than one-sided type-I error level) and will typically
lead to type-I errors close to α if prior information is
weak. Importantly, despite the approximate equality of p-
values and Bayesian threshold probabilities, their meaning
is different (Casella and Berger22, Berger and Selke23,
Wasserstein and Lazar1). In addition, the decision value
in a dual-criterion design and the alternative hypothesis in
a standard design have entirely different interpretations. It
is therefore critical to elicit the decision value properly
from clinical considerations. Simply taking the alternative
hypothesis from a standard design as the decision value in
a dual-criterion design is unwarranted.
For example, for a standard time-to-event design with
80% power at a one-third hazard reduction (HR=0.667), the
implied effect size threshold (minimum effect estimate for
success) is 0.754. Using 0.667 as the decision value in a dual-
criterion trial implies a completely different design. First,
the standard design would not fulfill the clinically relevant
criterion (estimate threshold 0.754 instead of 0.667). Second,
because the dual-criterion is obviously more demanding, the
resulting power of the study is less compared to the standard
design. For instance, the power at 0.667 is 50% compared to
80% for the standard design.
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Sample size
After the design inputs α, null value (NV), and decision
value (DV) have been set, the sample size can be derived.
For normally distributed data, the minimum sample size is
nmin =
σ2 × zα2
(NV −DV )2
Here, zα is the 100(1-α)%-quantile of the standard normal
distribution, and σ is the outcome standard deviation; for
example, σ is 2 (under equal randomization) for the standard
normal approximation to time-to-event data.
The nmin above is the minimum sample size that implies
statistical significance if the effect estimate equals the
decision value. Importantly, the sample size of a dual-
criterion design must be at least nmin. It can of course be
larger than nmin if operating characteristics are considered
unsatisfactory otherwise.
For non-normal data, a grid search over sample sizes may
be needed to determine the minimum sample size. A search
over increasing sample sizes is performed until the sample
size nmin is found so that for all sample sizes equal to
or larger than nmin, the dual-criterion is fulfilled. For an
example, see the single-arm trial design in the next section.
Operating characteristics
Operating characteristics (type-I error, power) are an integral
part of clinical trials designs and should be provided in the
study protocol.
For dual-criterion designs, it is important to understand
that the power at the decision value is (approximately)
50%: if the true parameter equals the decision value, there
is a roughly equal chance that the effect estimate lies on
either side of the decision value. Notingly, increasing the
sample size will not change the power at the decision value:
for parameters superior to the decision value the power
increases, whereas for inferior values it decreases. This is
warranted because superior values justify a GO, whereas
inferior values do not. Thus, if the true value equals the
decision value, a power higher (lower) than 50% would
bias decisions towards GO (NO-GO), which is unwarranted.
Therefore, having 50% power at the decision value value
does not mean that the study is underpowered. Such a claim
fails to understand the difference between the decision value
of a dual-criterion design and the alternative parameter of a
standard design.
For the previous example, the minimum number of events
(nmin) is 309. The left panel of Figure 1 shows the operating
characteristics. If power for larger effects than the decision
value is considered unsatisfactory, the sample size should
be increased. However, for larger sample sizes, the effect
estimate may not reach the decision value even if statistical
significance holds, which is the inconclusive case 3 in
Table 2. Moreover, larger sample sizes reduce the type-I
error below the required α. The right panel of Figure 1
shows the operating characteristics for 420 events: for effect
sizes superior to the decision value (HR ≤ 0.8), the power
increases compared to 309 events, whereas for inferior values
it decreases.
[Figure 1 about here.]
In addition to the operating characteristics of a dual-
criterion design, data scenarios (effect estimates) with
corresponding decisions may help to clarify decisions
obtained from a dual-criterion design.
Final analysis
The final analysis of a trial with a dual-criterion design does
not differ from other designs. One needs to calculate the
respective frequentist or Bayesian metrics:
• the p-value (or one-sided confidence interval) and the
parameter estimate (e.g. the unbiased or maximum-
likelihood estimate)
• the posterior probability that the parameter is better
than the null-value and the posterior median (or
mean). In addition, ploting the posterior density and
cumulative distribution function may be useful.
For phase II trials, the ultimate GO or NO-GO decision
is based on these dual-criterion metrics and other possibly
relevant information.
Examples
We now discuss two recent implementations of dual-criterion
designs in phase II. To illustrate the broad applicability of
such designs, we consider a randomized controlled trial with
a time-to-event endpoint and a single-arm trial with a binary
endpoint. The implementation will be frequentist for the first
and Bayesian for the second. We also investigate alternative
designs (Rubinstein et al.11, Sargent et al.9), which shows
similarities as well as differences in comparison to the dual-
criterion design.
A randomized PoC design with time-to-event
data
Example 1 was a randomized, double-blind PoC study of
an experimental drug in combination with standard of care
in patients with non-small-cell lung cancer. Patients were
randomized equally to the experimental drug plus standard of
care or to standard of care alone. The primary endpoint was
progression-free survival (PFS), assessed with a log-rank test
and Cox regression with treatment as a covariate.
In addition to the null value of no effect (HR=1), the
specification of the decision value took into account standard
of care data, the competitive landscape, and discussions
with clinicians, marketing experts, and health authorities. A
literature review revealed a median PFS of approximately
five months. Based on discussions with experts, an estimated
improvement of at least two months, which corresponds
to an approximate HR of 0.7, was deemed necessary
to be clinically meaningful. Values larger than 0.7 were
judged unsatisfactory to clearly justify further development
of the experimental drug. The dual-criterion for further
development (GO) of the experimental drug was thus
1. statistical significance: one-sided p-value of log-rank
test ≤ 0.1
2. clinical relevance: estimated HR from Cox regression
≤ 0.70
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The sample size calculation used approximate normality
of the log-hazard-ratio. From the sample size formula in
previous section, the minimum number of events nmin is
52. That is, with at least 52 events, if the estimated HR is
0.7, the one sided p-value is 0.1. To improve the power of
the study for effect sizes better than 0.7 (decision value),
the number of PFS events was increased to 70. To reach
70 events, approximately 200 patients (100 per arm) were
expected to be enrolled.
Table 3 shows the operating characteristics of the design,
that is, the probability for a GO, NO-GO, or inconclusive
outcome.Design 1 was the actually used design. Since 70
exceeds the minimal number of events (52), an inconclusive
decision (significant p-value with an estimate inferior to the
estimate threshold 0.7) may occur. However, this probability
is less than 0.1 for all hazard ratio scenarios. The type-I error
is 0.032, considerably less than the required 0.1, and the
power is reasonably large for convincing hazard ratios (0.92
for HR 0.5, 0.74 for HR 0.6).
The second design considers the case of 52 events, the
minimum number such that statistical significance implies
clinical relevance (hazard ratio estimate = 0.7). As can be
seen, inconclusive decisions cannot arise. Compared to the
first design, the type-I error is now the postulated 0.1, and
the power is smaller (compared to design 1) for hazard ratios
superior to the 0.7 threshold. The probability that the study
fails is larger for hazard ratios inferior to 0.7.
For comparison, we now look at three more classical
designs with different choices for type-I error and power at
an alternative hazard ratio of 0.5, referred to as Randomized
Screening Designs by Rubinstein et al.11. Design 3 is the
most demanding, with one-sided type-I error 0.1 and power
0.9. The number of events is 55, and statistical significance
is achieved if the hazard ratio estimate is better than 0.708; in
the actual trial such an estimate would have been insufficient
for a GO decision. The sample size and estimate threshold
are similar to design 2, so type-I error and power are similar
too. Power is slightly higher due to the larger number of
events and the weaker estimate threshold (0.708 compared
to 0.7). However, design 1 differs in two aspects: if the
sample size is larger than nmin, inconclusive decisions may
arise (statistical significance but clinical irrelevance); and,
the type-I error will be smaller than α.
Design 4 shows an example with the same type-I error
(0.1) but decreased power (0.8). The implied required hazard
ratio estimate is now 0.659, which is clearly more aggressive
than the explicitly postulated 0.7 in the dual-criterion design.
Finally, design 5 uses type-I error 0.2 and power 0.9.
This allows for more GO decisions: the required hazard
ratio estimate is now only 0.761, in stark contrast to the
clinically relevant value of 0.7. If an estimated 24% hazard
reduction had been considered sufficient for a clear GO, a
dual-criterion design with decision value 0.76 would have
been an alternative to design 5.
[Table 3 about here.]
A single-arm PoC design with binary data
Example 2 was a single-arm PoC trial of an experimental
drug in Chinese patients with non-small-cell lung cancer.
This type of study is common in early phase Oncology trials,
for example in the expansion phase of a dose-escalation trial.
The primary endpoint was objective response rate (ORR),
which quantifies the preliminary efficacy of the experimental
drug. The final analysis, which was Bayesian in this example,
used a binomial sampling and a minimally informative
unimodal Beta prior distribution with mean 0.075, that is,
a Beta(0.0811,1) distribution.
While the null value is usually clear (no effect) in
randomized trials, selecting it is more challenging in single-
arm trials due to the absence of a comparator. Based on
a literature review and clinical discussions, the null value
for the ORR was set to 7.5%. Moreover, a minimum
improvement of 10% was considered necessary to justify
further development. The dual-criterion was thus defined as
1. Bayesian statistical significance: pr( ORR ≥ 7.5% |
data) ≥ 0.95
2. clinical relevance: posterior median ≥ 17.5%
For this dual-criterion, the minimally required sample size
nmin is 22; that is, for n ≥ 22, clinical relevance (criterion 2)
ensures statistical significance (criterion 1). The final sample
size of the trial was set to 25. Figure 2 shows the posterior
probability that the ORR exceeds 7.5% as a function of n,
assuming that the number of responders is the smallest r such
that the posterior median exceeds the decision value 17.5%.
[Figure 2 about here.]
For n=25, the minimum number of responders required
for a GO is five, with respective estimate 18.7% (posterior
median) and posterior probability for a positive effect (ORR
≥ 7.5%) of 0.967. If the number of responders is less than
five, both criteria are missed (NO-GO): for four responders,
the posterior median is 14.8% and the probability of a
positive effect is 0.895. Thus, in contrast to example 1, there
will be no inconclusive outcome here.
Table 4 shows the designs’s probabilities of GO or NO-
GO (design 1). The type-I error is 0.036, and the power was
considered reasonably large.
For comparison, we consider a three-outcome design with
H0: ORR ≤ 7.5%, H1: ORR ≥ 27.5%, α = 0.05, β = 0.1,
η = 0.8 and pi = 0.9, which requires 27 patients (for details
see Sargent et al.9). The decisions are as follows: NO-GO
for zero to three responders, GO for five or more responders,
and inconclusive for four responders.
For comparison to the three-outcome design, assume a
larger size (n=36). Now, to meet the dual-criterion, seven
responders are necessary: for this, the posterior median is
18.5%, and the probability of a positive effect is 0.985.
An inconclusive outcome would occur for six responders:
the posterior median is 15.8% (missing clinical relevance),
yet the posterior probability of a positive effect is 0.954,
reaching the 0.95 threshold. The operating characteristics
for this design are also shown in Table 4 (design 2). The
comparison to the three-outcome design is interesting. The
type-I error α and type-II error (for a response rate 0.275) are
both small (0.016 and 0.044). In addition, the probability for
NO-GO under the null hypothesis is 0.95, and the probability
for GO is 0.902 for a response rate of 0.275. Both exceed 0.8,
as suggested by Sargent et al.9. This shows that this dual-
criterion design is a three-outcome design with desirable
properties.
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Finally, design 3 in Table 4 shows possible differences
between a dual-criterion and a three-outcome design. First,
note that the operating characteristics reveal small error
rates and reasonably large power, implying a three-outcome
design with acceptable properties. Of special interest is
the inconclusive outcome (four responders in 27 patients):
the posterior median is 13.7% and the probability of a
positive effect (ORR ≥ 7.5%) is 0.869. Thus, the dual-
criterion fails for both (Bayesian) statistical significance
and clinical relevance (NO-GO), whereas the three-outcome
design results in an inconclusive outcome.
[Table 4 about here.]
The computations for the two examples of this section
were done with R 3.224. Code is available from the main
author upon request.
Discussion
The development plan of each experimental drug is unique,
for which phase II trials are an important screening or early
examination step. A good phase II design should be based
on clinical needs, already available information about the
drug, and the competitive landscape. In addition, it must
have acceptable error rates for well-defined success criteria.
For comparative efficacy trials, standard designs aim for
a statistically significant p-value under type-I error control
and sufficiently large power. However, statistical significance
only guarantees sufficient evidence that the drug has an
effect. It does not guarantee clinical relevance.
We have discussed a dual success criterion that goes
beyond a single null-metric, a p-value (Wasserstein and
Lazar1) or posterior threshold probability. The criterion
complements statistical significance by a sufficiently
large effect estimate. The latter is easily interpretable,
ensuring clinical relevance if success is declared. Whether
a frequentist or Bayesian design is chosen is rather
unimportant in the absence of prior information. Otherwise,
a Bayesian implementation is preferred.
There are similarities for dual-criterion and standard
designs. Type-I error α and power (1− β) are important for
both. For standard designs, they define the design, leading
to an implicit success threshold for the effect estimate.
To guarantee clinical relevance (a sufficiently large effect
estimate), the effect threshold can be changed by changing α
and β. Alternatively, and more directly, a dual-criterion can
be used. This, however, has no explicit power requirements,
and power should therefore be assessed. Irrespective of
the chosen design, the three main metrics (type-I error,
power, estimation threshold for success) must be understood
to ensure a sensible balance of statistical and clinical
requirements.
Beyond these similarities, differences between the two
designs should be kept in mind. First, standard designs
always result in success (statistical significance) or failure.
Dual-criterion designs may lead to a statistically significant
but clinically irrelevant result. As we have shown, such
inconclusive outcomes are possible if the sample size is
larger than the minimum sample size that implies statistical
significance if the estimate reaches the clinical success
threshold. Second, for standard designs, increasing the
sample size increases the power for effects better than the
null. For dual-criterion designs, power is only increased for
values superior to the decision value since inferior values are
clinically irrelevant.
The specification of a dual-criterion should be tailored
to the development plan. While conceptually simple, its
implementation requires care. We have experienced two
related challenges. First, the elicitation of the decision value,
the threshold for the effect estimate, is sometimes considered
challenging. However, if carefully done, elicitation of the
decision value is often easier for clinicians compared to an
alternative hypothesis with respective power. Second, the
fact that study power is 50% at the decision value has let
some reviewers conclude that the study is underpowered.
This concern can be alleviated in the protocol by precisely
defining the dual-criterion, clarifying that the decision value
differs from the alternative hypothesis in a standard design,
and providing the power for effect parameters considerably
better than the decision value.
We have only discussed the dual-criterion design for
two simple phase II examples. A dual-criterion can of
course be applied in other settings too because requirements
of statistical significance and a reasonably large effect
estimate are generally applicable. Examples include non-
inferiority (Neuenschwander et al.18), bridging, and dose-
finding studies, as well as multiple endpoints. In addition,
dual-criterion designs may include interim analyses for
futility for which we often use probability of success for
interim decisions (Gsponer et al.25).
Finally, our experience so far has been confined to
nonconfirmatory trials. In the confirmatory setting, the size
of effect estimates matters but is usually not part of the
success criterion. However, a formal criterion may help to
avoid negative surprises, in particular for large trials: rather
than questioning the relevance of a significant phase III trial
with an unconvincing effect estimate, formally introducing
the minimum effect estimate in the success criterion may be
a better option.
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Figure 1. Operating characteristics of dual-criterion designs with 309 and 420 number of events.
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Figure 2. Example 2: grid search for minimum sample size.
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Table 1. Design components for standard, dual-criterion, and precision designs.
standard design dual-criterion design precision design
null value required required -
alternative value required - -
decision value (implied) required -
type-I error required required -
power required (implied) -
precision of estimate (implied) (implied) required
sample size (implied) (implied) (implied)
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not relevant relevant
(1) (4)
not significant NO-GO inconclusive
insufficient evidence
of relevant efficacy
(3) (2)
significant inconclusive GO
evidence of
relevant efficacy
Table 2. Outcomes and decisions for a dual-criterion design.
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Table 3. Example 1: operating characteristics for dual-criterion and standard designs; probabilities for GO, NO-GO and
inconclusive decisions given by hazard ratio estimate θˆ.
1. dual-criterion design: α=0.1, DV=0.7, n=70
true HR GO: θˆ ≤ 0.7 NO-GO: θˆ > 0.736 inconclusive
0.5 0.920 0.053 0.027
0.6 0.740 0.196 0.064
0.7 0.500 0.417 0.083
0.8 0.288 0.636 0.076
0.9 0.147 0.800 0.054
1.0 0.068 0.900 0.032
2. dual-criterion design: α = 0.1, DV=0.7, n=52
GO: θˆ ≤ 0.7 NO-GO: θˆ > 0.7 inconclusive
0.5 0.887 0.113 —
0.6 0.711 0.289 —
0.7 0.500 0.500 —
0.8 0.315 0.685 —
0.9 0.182 0.818 —
1.0 0.099 0.901 —
3. standard design: α = 0.1, β = 0.1(θA = 0.5), n=55
GO: θˆ ≤ 0.708 NO-GO: θˆ > 0.708 inconclusive
0.5 0.901 0.099 —
0.6 0.729 0.270 —
0.7 0.516 0.484 —
0.8 0.325 0.675 —
0.9 0.186 0.813 —
1.0 0.100 0.900 —
4. standard design: α = 0.1, β = 0.2(θA = 0.5), n=38
GO: θˆ ≤ 0.659 NO-GO: θˆ > 0.659 inconclusive
0.5 0.804 0.196 —
0.6 0.615 0.385 —
0.7 0.428 0.572 —
0.8 0.276 0.724 —
0.9 0.169 0.831 —
1.0 0.100 0.900 —
5. standard design: α = 0.2, β = 0.1(θA = 0.5), n=38
GO: θˆ ≤ 0.761 NO-GO: θˆ > 0.761 inconclusive
0.5 0.902 0.098 —
0.6 0.768 0.232 —
0.7 0.602 0.398 —
0.8 0.439 0.561 —
0.9 0.303 0.697 —
1.0 0.200 0.800 —
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Table 4. Example 2: operating characteristics for dual-criterion and three-outcome designs; probabilities for GO, NO-GO and
inconclusive decisions given by the number of responders (r).
1. dual-criterion design: α=0.05, DV=0.175, n=25
true ORR (%) GO: r ≥ 5 NO-GO: r < 5 inconclusive
7.5 0.036 0.964 —
12.5 0.195 0.805 —
17.5 0.451 0.549 —
22.5 0.693 0.307 —
27.5 0.858 0.142 —
2. dual-criterion design: α=0.05, DV=0.175, n=36
GO: r ≥ 7 NO-GO: r ≤ 5 inconclusive: r = 6
7.5 0.016 0.950 0.033
12.5 0.156 0.709 0.135
17.5 0.446 0.380 0.174
22.5 0.731 0.149 0.121
27.5 0.902 0.044 0.054
3. three-outcome design: n=27
GO: r ≥ 5 NO-GO: r ≤ 3 inconclusive: r = 4
7.5 0.048 0.860 0.092
12.5 0.243 0.558 0.199
17.5 0.523 0.280 0.197
22.5 0.759 0.113 0.128
27.5 0.901 0.038 0.062
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